Svb Leerink assumed coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report issued on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $28.00 target price on the stock.
Several other research analysts have also recently commented on the company. Robert W. Baird started coverage on Castle Biosciences in a research report on Monday. They set an outperform rating and a $27.00 price target for the company. Canaccord Genuity initiated coverage on Castle Biosciences in a research report on Monday. They set a buy rating and a $26.00 price target for the company. Finally, Leerink Swann initiated coverage on Castle Biosciences in a research note on Monday. They issued an outperform rating and a $28.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $26.80.
Shares of NASDAQ CSTL opened at $19.93 on Monday. Castle Biosciences has a 52 week low of $17.11 and a 52 week high of $24.75.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Read More: What is a death cross?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.